{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:45:58Z","timestamp":1791215158239,"version":"4.1.0"},"publisher-location":"Berlin, Heidelberg","reference-count":61,"publisher":"Springer Berlin Heidelberg","isbn-type":[{"value":"9783642273391","type":"print"},{"value":"9783642273407","type":"electronic"}],"license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013]]},"DOI":"10.1007\/978-3-642-27340-7_13","type":"book-chapter","created":{"date-parts":[[2013,3,5]],"date-time":"2013-03-05T16:21:10Z","timestamp":1362500470000},"page":"321-342","source":"Crossref","is-referenced-by-count":28,"title":["Treatment of Chronic Hepatitis C: Current and Future"],"prefix":"10.1007","author":[{"given":"Jean-Michel","family":"Pawlotsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"13_CR1","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","volume":"364","author":"BR Bacon","year":"2011","unstructured":"Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F et al (2011) Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 364:1207\u20131217","journal-title":"N Engl J Med"},{"key":"13_CR2","unstructured":"Brainard DM, Perty A, van Dyck K, Nachbar RB, de Lepeleire I, Caro L, Stone JA et al (2010) Safety and antiviral activity of MK-5172, a novel HCV NS3\/4A protease inhibitor with potent activity against known resistance mutants, in genotype 1 and 3 HCV-infected patients. Hepatology 52:706A\u2013707A"},{"key":"13_CR3","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1053\/j.gastro.2006.07.022","volume":"131","author":"JP Bronowicki","year":"2006","unstructured":"Bronowicki JP, Ouzan D, Asselah T, Desmorat H, Zarski JP, Foucher J, Bourliere M et al (2006) Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology 131:1040\u20131048","journal-title":"Gastroenterology"},{"key":"13_CR4","unstructured":"Brown NA, Vig P, Ruby E, Muchnik A, Pottorf E, Knox SJ, Febbraro S et al (2010) Safety and pharmacokinetics of PPI-461, a potent new hepatitis C virus NS5A inhibitor with pan-genotype activity. Hepatology 52:S464"},{"key":"13_CR5","unstructured":"Chayama K, Takahashi S, Kawakami Y, Ikeda K, Suzuki F, Toyota J, Karino Y et al (2011) Dual oral combination therapy with the NS5A inhibitor BMS-790052 and the NS3 protease inhibitor BMS-650032 achieved 90% sustained virologic response (SVR12) in HCV genotype 1b-infected null responders. Hepatology 54:1428A"},{"issue":"1","key":"13_CR6","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/S0168-8278(11)60069-X","volume":"54","author":"S Chevaliez","year":"2011","unstructured":"Chevaliez S, Rodriguez C, Soulier A, Ahmed-Belkacem A, H\u00e9zode C, Pawlotsky JM (2011) Molecular characterization of HCV resistance to telaprevir by means of ultra-deep pyrosequencing: preexisting resistant variants and dynamics of resistant populations. J Hepatol 54(1):S30","journal-title":"J Hepatol"},{"key":"13_CR7","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1053\/j.gastro.2012.02.027","volume":"142","author":"S Chevaliez","year":"2012","unstructured":"Chevaliez S, Rodriguez C, Pawlotsky JM (2012) New virologic tools for management of chronic hepatitis B and C. Gastroenterology 142:1303\u20131313","journal-title":"Gastroenterology"},{"key":"13_CR8","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1053\/j.gastro.2011.12.057","volume":"142","author":"TW Chu","year":"2012","unstructured":"Chu TW, Kulkarni R, Gane EJ, Roberts SK, Stedman C, Angus PW, Ritchie B et al (2012) Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C. Gastroenterology 142:790\u2013795","journal-title":"Gastroenterology"},{"key":"13_CR9","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1128\/AAC.00939-08","volume":"53","author":"L Coelmont","year":"2008","unstructured":"Coelmont L, Kaptein S, Paeshuyse J, Vliegen I, Dumont JM, Vuagniaux G, Neyts J (2008) Debio 025, a cyclophilin binding molecule, is highly efficient in clearing HCV replicon containing cells, alone or when combined with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors. Antimicrob Agents Chemother 53:967\u2013976","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"13_CR10","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/S0168-8278(09)60090-8","volume":"50","author":"L Coelmont","year":"2009","unstructured":"Coelmont L, Gallay P, Bobardt M, Kaptein S, Paeshuyse J, Vliegen I, Vuagniaux G et al (2009) Particular in vitro anti-HCV activities and resistance profile of the cyclophylin inhibitor DEBIO-025. J Hepatol 50(1):S36","journal-title":"J Hepatol"},{"key":"13_CR11","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s11901-011-0101-7","volume":"10","author":"H Dahari","year":"2011","unstructured":"Dahari H, Guedj J, Perelson AS, Layden TJ (2011) Hepatitis C viral kinetics in the era of direct acting antiviral agents and IL28B. Curr Hepat Rep 10:214\u2013227","journal-title":"Curr Hepat Rep"},{"key":"13_CR12","unstructured":"de Bruijne J, de Rooij JV, van Vliet A, Leempoels J, Zhou XJ, Weegink C, Molenkamp R et al (2010) Phase I study in healthy volunteers and patients with IDX-375, a novel non-nucleoside HCV polymerase inhibitor. Hepatology 52:1219A"},{"issue":"1","key":"13_CR13","doi-asserted-by":"crossref","first-page":"S468","DOI":"10.1016\/S0168-8278(10)61203-2","volume":"52","author":"V Detishin","year":"2010","unstructured":"Detishin V, Haazen W, Robison H, Robarge L, Olek E (2010) Virological response, safety and pharmacokinetic profile following single- and multiple-dose administration of ACH-0141625 protease inhibitor to healthy volunteers and HCV genotype 1 patients. J Hepatol 52(1):S468","journal-title":"J Hepatol"},{"key":"13_CR14","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/135965350901400104","volume":"14","author":"A Erhardt","year":"2009","unstructured":"Erhardt A, Deterding K, Benhamou Y, Reiser M, Forns X, Pol S, Calleja JL et al (2009) Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment. Antiviral Ther 14:23\u201332","journal-title":"Antiviral Ther"},{"key":"13_CR15","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2011) EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 55:245\u2013264","DOI":"10.1016\/j.jhep.2011.02.023"},{"key":"13_CR16","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.jhep.2010.11.001","volume":"54","author":"N Forestier","year":"2011","unstructured":"Forestier N, Larrey D, Guyader D, Marcellin P, Rouzier R, Patat A, Smith P et al (2011) Treatment of chronic hepatitis C patients with the NS3\/4A protease inhibitor danoprevir (ITMN-191\/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study. J Hepatol 54:1130\u20131136","journal-title":"J Hepatol"},{"key":"13_CR17","doi-asserted-by":"crossref","first-page":"7312","DOI":"10.1128\/JVI.00253-11","volume":"85","author":"RA Fridell","year":"2011","unstructured":"Fridell RA, Qiu D, Valera L, Wang C, Rose RE, Gao M (2011) Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052. J Virol 85:7312\u20137320","journal-title":"J Virol"},{"key":"13_CR18","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S0140-6736(10)61384-0","volume":"376","author":"EJ Gane","year":"2010","unstructured":"Gane EJ, Roberts SK, Stedman CA, Angus PW, Ritchie B, Elston R, Ipe D et al (2010) Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 376:1467\u20131475","journal-title":"Lancet"},{"issue":"1","key":"13_CR19","doi-asserted-by":"crossref","first-page":"377A","DOI":"10.1002\/hep.24213","volume":"54","author":"EJ Gane","year":"2011","unstructured":"Gane EJ, Stedman CA, Hyland RH, Sorensen RD, Symonds WT, Hindes R, Berrey MM (2011) Once daily PSI-7977 plus RBV: pegylated interferon alfa not required for complete rapid viral response in treatment-naive patients with HCV GT2 or GT3. Hepatology 54(1):377A","journal-title":"Hepatology"},{"issue":"2","key":"13_CR20","doi-asserted-by":"crossref","first-page":"S438","DOI":"10.1016\/S0168-8278(12)61125-8","volume":"56","author":"EJ Gane","year":"2012","unstructured":"Gane EJ, Stedman CA, Hyland RH, Sorensen RD, Symonds WT, Hindes RG, Berrey MM (2012) ELECTRON: once daily PSI-7977 plus RBV in HCV GT1\/2\/3. J Hepatol 56(2):S438","journal-title":"J Hepatol"},{"key":"13_CR21","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature08960","volume":"465","author":"M Gao","year":"2010","unstructured":"Gao M, Nettles RE, Belema M, Snyder LB, Nguyen VN, Fridell RA, Serrano-Wu MH et al (2010) Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465:96\u2013100","journal-title":"Nature"},{"key":"13_CR22","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","volume":"49","author":"MG Ghany","year":"2009","unstructured":"Ghany MG, Strader DB, Thomas DL, Seeff LB (2009) Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49:1335\u20131374","journal-title":"Hepatology"},{"key":"13_CR23","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/hep.24641","volume":"54","author":"MG Ghany","year":"2011","unstructured":"Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB (2011) An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American association for the study of liver diseases. Hepatology 54:1433\u20131444","journal-title":"Hepatology"},{"key":"13_CR24","unstructured":"Goldwater R, DeMicco M, Zong JA, Chittik GE, Yuen GJ, West S, Kagel J et al (2010) Safety, pharmacokinetics and antiviral activity of single oral doses of the HCV NS3 protease inhibitor GS-9256. Hepatology 52:717A\u2013718A"},{"key":"13_CR25","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1002\/hep.24272","volume":"53","author":"J Guedj","year":"2011","unstructured":"Guedj J, Perelson AS (2011) Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration. Hepatology 53:1801\u20131808","journal-title":"Hepatology"},{"key":"13_CR26","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1053\/jhep.2003.50218","volume":"37","author":"E Herrmann","year":"2003","unstructured":"Herrmann E, Lee HJ, Marinos G, Modi M, Zeuzem S (2003) Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 37:1351\u20131358","journal-title":"Hepatology"},{"key":"13_CR27","unstructured":"Hotho D, deBruijne J, O\u2019Farrell A, Boyea T, Li J, Weegink CJ, Schinkel J et al (2009) Accelerated clinical trial design to assess the safety, tolerability and antiviral activity of PHX1766, a novel HCV NS3\/4A protease inhibitor in healthy volunteers and chronic hepatitis C patients. Hepatology 50:1031A\u20131032A"},{"key":"13_CR28","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","volume":"364","author":"IM Jacobson","year":"2011","unstructured":"Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P et al (2011) Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 364:2405\u20132416","journal-title":"N Engl J Med"},{"key":"13_CR29","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/hep.21781","volume":"46","author":"TL Kieffer","year":"2007","unstructured":"Kieffer TL, Sarrazin C, Miller JS, Welker MW, Forestier N, Reesink HW, Kwong AD et al (2007) Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 46:631\u2013639","journal-title":"Hepatology"},{"issue":"1","key":"13_CR30","doi-asserted-by":"crossref","first-page":"S383","DOI":"10.1016\/S0168-8278(09)61056-4","volume":"50","author":"D Larrey","year":"2009","unstructured":"Larrey D, Benhamou Y, Lohse AW, Trepo C, Moelleken C, Bronowicki JP, Arasteh K et al (2009) Safety, pharmacokinetics and antiviral effect of BI207127, a novel HCV RNA polymerase inhibitor, after 5 days oral treatment in patients with chronic hepatitis C. J Hepatol 50(1):S383\u2013S384","journal-title":"J Hepatol"},{"key":"13_CR31","first-page":"403A","volume":"48","author":"E Lawitz","year":"2008","unstructured":"Lawitz E, Sulkowski M, Jacobson I, Faruqui S, Kraft WK, Maliakkal B, Allbrahim M et al (2008) Safety, tolerability and antiviral activity of MK-7009, a novel inhibitor of the hepatitis C virus NS3\/4A protease, in patients with chronic HCV genotype 1 infection. Hepatology 48:403A","journal-title":"Hepatology"},{"issue":"1","key":"13_CR32","doi-asserted-by":"crossref","first-page":"S384","DOI":"10.1016\/S0168-8278(09)61057-6","volume":"50","author":"E Lawitz","year":"2009","unstructured":"Lawitz E, Rodriguez-Torres M, DeMicco M, Nguyen T, Godofsky E, Appleman J, Rahimy M et al (2009) Antiviral activity of ANA598, a potent non-nucleoside polymerase inhibitor, in chronic hepatitis C patients. J Hepatol 50(1):S384","journal-title":"J Hepatol"},{"key":"13_CR33","doi-asserted-by":"crossref","unstructured":"Lawitz E, Gaultier I, Poordad F, De Jesus E, Kowdley K, Sepulveda G, Cohen D et al (2010) Four week virologic response and safety of ABT-450 given with low-dose ritonavir (ABT-450r) in combination with pegylated interferon alfa-2a and ribavirin after 3-day monotherapy in genotype 1 HCV-infected treatment-naive subjects. Hepatology 52:878A\u2013879A","DOI":"10.1016\/S0168-8278(11)61222-1"},{"key":"13_CR34","doi-asserted-by":"crossref","unstructured":"Lawitz E, Hill JM, Marbury TC, Rodriguez-Torres M, DeMicco M, Quesada J, Shaw P et al (2010) Three-day, dose-ranging study of the HCV NS3 protease inhibitor GS-9451. Hepatology 52:714A\u2013715A","DOI":"10.1016\/S0168-8278(10)61199-3"},{"key":"13_CR35","unstructured":"Lawitz E, Rodriguez-Torres M, Denning J, Cornpropst M, Clemons D, McNair L, Berrey M et al (2011) Once daily dual nucleotide combination of PSI-938 and PSI-7977 provides 94% HCV RNA\u00a0<\u00a0LOD at day 14: first purine\/pyrimidin clinical combination data (the NUCLEAR study). J Hepatol 54:S543"},{"issue":"1","key":"13_CR36","doi-asserted-by":"crossref","first-page":"S481","DOI":"10.1016\/S0168-8278(11)61221-X","volume":"54","author":"E Lawitz","year":"2011","unstructured":"Lawitz E, Gruener D, Hill J, Marbury T, Komjathy S, DeMicco M, Murillo A et al (2011b) Three-day dose ranging study of the HCV NS5A inhibitor GS-5885. J Hepatol 54(1):S481\u2013S482","journal-title":"J Hepatol"},{"key":"13_CR37","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1056\/NEJMoa1104430","volume":"366","author":"AS Lok","year":"2012","unstructured":"Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, Ghalib R, Reindollar R et al (2012) Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 366:216\u2013224","journal-title":"N Engl J Med"},{"key":"13_CR38","doi-asserted-by":"crossref","first-page":"1023A","DOI":"10.1002\/hep.22502","volume":"48","author":"MP Manns","year":"2008","unstructured":"Manns MP, Reesink H, Moreno C, Berg T, Benhamou Y, Horsmans Y, Dusheiko G et al (2008) Safety and antiviral activity of TMC435350 in treatment-naive genotype 1 HCV-infected patients. Hepatology 48:1023A","journal-title":"Hepatology"},{"key":"13_CR39","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.jhep.2010.08.040","volume":"54","author":"MP Manns","year":"2011","unstructured":"Manns MP, Bourliere M, Benhamou Y, Pol S, Bonacini M, Trepo C, Wright D et al (2011) Potency, safety, and pharmacokinetics of the NS3\/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. J Hepatol 54:1114\u20131122","journal-title":"J Hepatol"},{"key":"13_CR40","unstructured":"Nettles R, Chien C, Chung E, Persson A, Gao M, Belema M, Meanwell NA et al (2008) BMS-790052 is a first-in-class potent hepatitis C virus NS5A inhibitor for patients with chronic HCV infection: results from a proof-of-concept study. Hepatology 48:1025A"},{"key":"13_CR41","unstructured":"Nettles R, Wang XD, Quadri S, Wu YS, Gao M, Belema M, Lawitz E et al (2010) BMS-824393 is a potent HCV NS5A inhibitor with substantial antiviral activity when given as monotherapy in subjects with chronic genotype 1 HCV infection. Hepatology 52:1203A\u20131204A"},{"key":"13_CR42","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1002\/hep.24262","volume":"53","author":"JM Pawlotsky","year":"2011","unstructured":"Pawlotsky JM (2011) Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology 53:1742\u20131751","journal-title":"Hepatology"},{"key":"13_CR43","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1053\/j.gastro.2003.12.002","volume":"126","author":"JM Pawlotsky","year":"2004","unstructured":"Pawlotsky JM, Dahari H, Neumann AU, Hezode C, Germanidis G, Lonjon I, Castera L et al (2004) Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology 126:703\u2013714","journal-title":"Gastroenterology"},{"key":"13_CR44","doi-asserted-by":"crossref","unstructured":"Picard O, Cacoub P (2012) Dermatological adverse effects during genotype-1 hepatitis C treatment with the protease inhibitors telaprevir and boceprevir. Patient management. Clin Res Hepatol Gastroenterol 36:437\u2013440","DOI":"10.1016\/j.clinre.2012.02.004"},{"key":"13_CR45","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","volume":"364","author":"F Poordad","year":"2011","unstructured":"Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM et al (2011) Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364:1195\u20131206","journal-title":"N Engl J Med"},{"issue":"2","key":"13_CR46","doi-asserted-by":"crossref","first-page":"S559","DOI":"10.1016\/S0168-8278(12)61430-5","volume":"56","author":"FF Poordad","year":"2012","unstructured":"Poordad FF, Lawitz EJ, Reddy KR, Afdhal NH, Hezode C, Zeuzem S, Lee SS et al (2012) A randomized trial comparing ribavirin dose reduction versus erythropoietin for anemia management in previously untreated patients with chronic hepatitis C receiving boceprevir plus peginterferon\/ribavirin. J Hepatol 56(2):S559","journal-title":"J Hepatol"},{"key":"13_CR47","doi-asserted-by":"crossref","first-page":"20509","DOI":"10.1073\/pnas.1105797108","volume":"108","author":"MH Powdrill","year":"2011","unstructured":"Powdrill MH, Tchesnokov EP, Kozak RA, Russell RS, Martin R, Svarovskaia ES, Mo H et al (2011) Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance. Proc Natl Acad Sci USA 108:20509\u201320513","journal-title":"Proc Natl Acad Sci USA"},{"key":"13_CR48","unstructured":"Reddy R, Rodriguez-Torres M, Gane EJ, Robson R, Lalezari J, Everson GT, DeJesus E et al (2007) Antiviral activity, pharmacokinetics, safety and tolerability of R7128, a novel nucleoside HCV RNA polymerase inhibitor, following multiple, ascending oral doses in patients with HCV genotype 1 infection who have failed prior interferon therapy. Hepatology 46:862A\u2013863A"},{"issue":"1","key":"13_CR49","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/S0168-8278(09)60088-X","volume":"50","author":"H Reesink","year":"2009","unstructured":"Reesink H, Bergmann J, de Bruijne J, Weegink C, van Lier J, van Vliet A, Keung A et al (2009) Safety and antiviral activity of SCH 900518 administered as monotherapy and in combination with peginterferon alfa-2b to naive and treatment-experienced HCV-1 infected patients. J Hepatol 50(1):S35","journal-title":"J Hepatol"},{"issue":"2","key":"13_CR50","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/S0168-8278(12)60072-5","volume":"56","author":"HW Reesink","year":"2012","unstructured":"Reesink HW, Janssen HLA, Zeuzem S, Lawitz EJ, Rodriguez-Torres M, Patel K, Chen A et al (2012) Final results. Randomized, double-blind, placebo-controlled safety, antiviral proof-of-concept study of miravirsen, an oligonucleotide targeting miR-122, in treatment-naive patients with genotype 1 chronic HCV infection. J Hepatol 56(2):S26","journal-title":"J Hepatol"},{"issue":"1","key":"13_CR51","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/S0168-8278(10)60033-5","volume":"52","author":"M Rodriguez-Torres","year":"2010","unstructured":"Rodriguez-Torres M, Lawitz E, Conway B, Kaita K, Sheikh A, Ghalib R, Adrover R et al (2010) Safety and antiviral activity of the HCV non-nucleoside polymerase inhibitor VX-222 in treatment-naive genotype 1 HCV infected patients. J Hepatol 52(1):S14","journal-title":"J Hepatol"},{"issue":"1","key":"13_CR52","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/S0168-8278(11)60064-0","volume":"54","author":"R Rouzier","year":"2011","unstructured":"Rouzier R, Larrey D, Gane EJ, Wiercinska-Drapalo A, Chang L, Zhang Y, Gujral B et al (2011) Activity of danoprevir plus low-dose ritonavir in combination with peginterferon alfa-2a plus ribavirin in previous null-responders. J Hepatol 54(1):S28","journal-title":"J Hepatol"},{"key":"13_CR53","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1053\/j.gastro.2007.02.037","volume":"132","author":"C Sarrazin","year":"2007","unstructured":"Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Muh U, Welker M, Wincheringer D et al (2007) Dynamic HCV genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir (VX-950). Gastroenterology 132:1767\u20131777","journal-title":"Gastroenterology"},{"key":"13_CR54","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1056\/NEJMoa1014463","volume":"365","author":"KE Sherman","year":"2011","unstructured":"Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, Fried MW et al (2011) Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 365:1014\u20131024","journal-title":"N Engl J Med"},{"issue":"2","key":"13_CR55","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/S0168-8278(12)60028-2","volume":"56","author":"F Suzuki","year":"2012","unstructured":"Suzuki F, Ikeda K, Toyota J, Karino Y, Ohmura T, Chayama K, Takahashi S et al (2012) Dual oral therapy with the NS5A inhibitor daclatasvir (BMS-790052) and NS3 protease inhibitor asunaprevir (BMS-650032) in HCV genotype 1b-infected null responders or ineligible\/intolerant to peginterferon\/ribavirin. J Hepatol 56(2):S7","journal-title":"J Hepatol"},{"key":"13_CR56","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2010.07.009","volume":"139","author":"MG Swain","year":"2010","unstructured":"Swain MG, Lai MY, Shiffman ML, Cooksley WG, Zeuzem S, Dieterich DT, Abergel A et al (2010) A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 139:1593\u20131601","journal-title":"Gastroenterology"},{"key":"13_CR57","doi-asserted-by":"crossref","first-page":"6353","DOI":"10.1128\/JVI.00215-11","volume":"85","author":"P Targett-Adams","year":"2011","unstructured":"Targett-Adams P, Graham EJ, Middleton J, Palmer A, Shaw SM, Lavender H, Brain P et al (2011) Small molecules targeting hepatitis C virus-encoded NS5A cause subcellular redistribution of their target: insights into compound modes of action. J Virol 85:6353\u20136368","journal-title":"J Virol"},{"key":"13_CR58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3851\/IMP2125","volume":"23","author":"E Thomas","year":"2012","unstructured":"Thomas E, Ghany MG, Liang TJ (2012) The application and mechanism of action of ribavirin in therapy of hepatitis C. Antivir Chem Chemother 23:1\u201312","journal-title":"Antivir Chem Chemother"},{"key":"13_CR59","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/hep.24342","volume":"54","author":"F Wagner","year":"2011","unstructured":"Wagner F, Thompson R, Kantaridis C, Simpson P, Troke PJ, Jagannatha S, Neelakantan S et al (2011) Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1-infected patients. Hepatology 54:50\u201359","journal-title":"Hepatology"},{"key":"13_CR60","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","volume":"364","author":"S Zeuzem","year":"2011","unstructured":"Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R et al (2011) Telaprevir for retreatment of HCV infection. N Engl J Med 364:2417\u20132428","journal-title":"N Engl J Med"},{"key":"13_CR61","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/hep.24744","volume":"55","author":"S Zeuzem","year":"2012","unstructured":"Zeuzem S, Buggisch P, Agarwal K, Marcellin P, Sereni D, Klinker H, Moreno C et al (2012) The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. Hepatology 55:749\u2013758","journal-title":"Hepatology"}],"container-title":["Current Topics in Microbiology and Immunology","Hepatitis C Virus: From Molecular Virology to Antiviral Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-642-27340-7_13","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T22:06:35Z","timestamp":1715033195000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-642-27340-7_13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"ISBN":["9783642273391","9783642273407"],"references-count":61,"URL":"https:\/\/doi.org\/10.1007\/978-3-642-27340-7_13","relation":{},"ISSN":["0070-217X","2196-9965"],"issn-type":[{"value":"0070-217X","type":"print"},{"value":"2196-9965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013]]}}}